Effectiveness and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus: A Multicenter, Prospective, Observational Study
Authors' conclusion
Evogliptin reduces blood glucose levels and is well-tolerated when used as an add-on, as a switch from other dipeptidyl peptidase 4 inhibitors, or as part of an initial combination therapy in patients with type 2 diabetes mellitus.
Study context
- Population
- Patients with T2D treated with evogliptin combined with other antidiabetic agents, 51 hospitals in South Korea1,596 in effectiveness set
- Participants
- 1,920 patients
- Exposure
- Evogliptin as add-on, switching or initial combination
- Outcome
- Change in haemoglobin A1c (HbA1c) (%) from baseline
- Follow-up
- 12 weeks
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
Change in HbA1c
Evogliptin add-on
−0.8
mean · ± 1.2% · %
Evogliptin-switching
−0.3
mean · ± 0.8% · %
Initial combination
−1.9
mean · ± 1.4% · %
Observational data: associations, not effects.
Safety
- Patients with adverse drug reactions (safety set, n=1920)
- 23
- No significant difference among the three groups
Original publication
Effectiveness and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus: A Multicenter, Prospective, Observational Study. Diabetes Obes Metab. Published 26 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →